Skip to content
APAXEN

APAXEN

NOVEL THERAPEUTIC DRUGS THAT INHIBIT NLRP3 INFLAMMASOMES TO TREAT INFLAMMATORY DISEASES, WITH A PRIMARY FOCUS ON PULMONARY ARTERIAL HYPERTENSION (PAH)

  • ABOUT US
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Inverstors
    • Partnership
  • PIPELINE
    • MFC-1040
  • SCIENCE
    • R&D Strategy
    • NLRP3 Inflammasome and MIF as therapeutic target
    • Targeted diseases
  • NEWS & MEDIA
  • REFERENCES
  • CAREERS
  • CONTACT

    PR – Apaxen raises €3.3 million in Series A Financing

    Press release
    11/09/201918/11/2019 by devin Press Releases

    Apaxen raises €3.3 million in Series A Financing to Develop Breakthrough Anti-inflammatory Therapeutics for Pulmonary Arterial Hypertension.

    Download the press release
    Télécharger le communiqué

    Post navigation

    Next PostBelgian biotech Apaxen appoints Bart Wuurman as CEO
    • ABOUT US
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Inverstors
      • Partnership
    • PIPELINE
      • MFC-1040
    • SCIENCE
      • R&D Strategy
      • NLRP3 Inflammasome and MIF as therapeutic target
      • Targeted diseases
    • NEWS & MEDIA
    • REFERENCES
    • CAREERS
    • CONTACT
    • ©APAXEN 2023
    • Privacy & GDPR
    • Website by Visible